Organization – Talk Bio

Cannes Lions 2025; IPG Health; Real Chemistry; Ogilvy Health; healthcare marketing; agency awards; Health & Wellness Lions; Grand Prix; AREA 23; Vaseline Verified

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

2 months ago talkbio0Tagged AACR, Budgets, Cancer Research, Congress (U.S. Legislature), federal, Funding, Malignant neoplasm of lung, NIH Mouse, Pancreatic carcinoma, public health policy

federal funding; cancer research; NIH budget cuts; Congress; lung cancer; pancreatic cancer; AACR; public health policy

Ex-HHS Workers Accuse Trump Administration of Using Flawed Data to Justify Mass Firings

2 months ago talkbio0Tagged Agencies, CHARGE Syndrome, disability services, firings, Medicare, Project, public servants, Trump administration

HHS firings; Trump administration; federal workforce; flawed data; Project 2025; agency cuts; disability services; Medicare; public servants

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

2 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

2 months ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs